Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $16,910.52 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,342 shares of Lexeo Therapeutics stock in a transaction on Monday, May 18th. The shares were sold at an average price of $5.06, for a total transaction of $16,910.52. Following the completion of the transaction, the chief executive officer owned 336,764 shares in the company, valued at approximately $1,704,025.84. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00.

Lexeo Therapeutics Stock Down 2.3%

Shares of NASDAQ:LXEO opened at $5.11 on Friday. The company has a market cap of $401.24 million, a price-to-earnings ratio of -3.52 and a beta of 1.52. The firm’s 50-day simple moving average is $5.88 and its 200-day simple moving average is $7.51. Lexeo Therapeutics, Inc. has a fifty-two week low of $2.51 and a fifty-two week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, research analysts forecast that Lexeo Therapeutics, Inc. will post -1.19 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Chardan Capital reissued a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Lexeo Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $18.88.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC raised its position in Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after acquiring an additional 1,850,211 shares during the last quarter. RA Capital Management L.P. acquired a new position in Lexeo Therapeutics during the fourth quarter worth about $49,650,000. Paradigm Biocapital Advisors LP acquired a new position in Lexeo Therapeutics during the fourth quarter worth about $47,299,000. Vestal Point Capital LP raised its position in Lexeo Therapeutics by 37.7% during the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after acquiring an additional 1,225,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Lexeo Therapeutics during the second quarter worth about $16,117,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.